

Anti-DLL4 Reference Antibody (U.Oxford patent anti-DLL4)

Catalog # APR11184

Product Information

Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q9NR61
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	74605

Additional Information



Target/Specificity	DLL4
Expression system	CHO

Protein Information


Name	DLL4
Function	Involved in the Notch signaling pathway as Notch ligand (PubMed: 11134954). Activates NOTCH1 and NOTCH4. Involved in angiogenesis; negatively regulates endothelial cell proliferation and migration and angiogenic sprouting (PubMed: 20616313). Essential for retinal progenitor proliferation. Required for suppressing rod fates in late retinal progenitors as well as for proper generation of other retinal cell types (By similarity). During spinal cord neurogenesis, inhibits V2a interneuron fate (PubMed: 17728344).
Cellular Location	Cell membrane; Single-pass type I membrane protein
Tissue Location	Expressed in vascular endothelium.

Images

Anti-DLL4 Reference Antibody (U.Oxford patent anti-DLL4) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.



The purity of Anti-DLL4 Reference Antibody (U.Oxford patent anti-DLL4) is 95.6%, determined by SEC-HPLC.



Immobilized HuDLL4-ECD-his at 2 µg/mL can bind U.Oxford patent anti-DLL4, EC₅₀= 0.0549 µg/mL.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.